Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) Short Interest Down 77.9% in August

Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) was the recipient of a large decrease in short interest in the month of August. As of August 14th, there was short interest totaling 8,194 shares, a decrease of 77.9% from the July 30th total of 37,127 shares. Approximately 0.2% of the shares of the stock are sold short. Based on an average trading volume of 64,625 shares, the days-to-cover ratio is presently 0.1 days.

Institutional Investors Weigh In On Regentis Biomaterials

An institutional investor recently bought a new stake in Regentis Biomaterials stock. AIGH Capital Management LLC bought a new stake in Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 300,000 shares of the company’s stock, valued at approximately $916,000. AIGH Capital Management LLC owned approximately 5.79% of Regentis Biomaterials at the end of the most recent quarter.

Regentis Biomaterials Stock Performance

Shares of RGNT traded down $0.06 during trading hours on Friday, hitting $2.00. 19,366 shares of the company were exchanged, compared to its average volume of 61,638. Regentis Biomaterials has a fifty-two week low of $1.23 and a fifty-two week high of $15.50. The firm’s fifty day moving average is $2.63 and its 200 day moving average is $2.92.

Regentis Biomaterials Company Profile

Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing tissue repair solutions which seek to restore the health. Regentis Biomaterials Ltd. is based in Herzliya, Israel.